[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368459-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368459-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-systematic-evaluation-of-the-therapeutic-potential-of-endogenous-adar-editors-in-cancer-prevention-and-treatment","A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment","","Adenosine deaminases acting on RNA (ADAR) enzymes provide a natural mechanism for A-to-I(G) RNA editing, creating genetic changes at the RNA level. Endogenous-ADAR editors use a programmed oligonucleotide to recruit native ADAR activity, enabling potential therapeutic correction of mutations. The study systematically maps correctable cancer mutations by analyzing germline predisposition variants and somatic driver mutations, highlighting clinically relevant targets. Results indicate meaningful reversion of predisposition variants and correction potential for driver mutations across cancer samples, supporting delivery feasibility via small payloads.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-systematic-evaluation-of-the-therapeutic-potential-of-endogenous-adar-editors-in-cancer-prevention-and-treatment/368459/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-systematic-evaluation-of-the-therapeutic-potential-of-endogenous-adar-editors-in-cancer-prevention-and-treatment/368459.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are endogenous-ADAR editors and how do they work?","Question",{"text":63,"@type":64},"They use a programmed oligonucleotide to attract native ADAR activity, enabling A-to-I(G) RNA editing at targeted sites for potential therapeutic correction.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the study assess which cancer mutations endogenous-ADAR can correct?",{"text":68,"@type":64},"It systematically evaluates correctable mutations by analyzing germline single nucleotide variants in cancer predisposition genes and examining somatic mutations across multiple cancer types.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic value does the study suggest for cancer prevention and treatment?",{"text":72,"@type":64},"It suggests that endogenous-ADAR may revert a substantial fraction of predisposition variants and has potential to correct at least one driver mutation in a large portion of samples, supporting future treatment strategies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368459,1790220041,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment  \nRona Merdler-Rabinowicz 1 ,2 ,3 ,†, Ariel Dadush 2 ,3 ,†, Sumeet Patiyal 1 , Padma Sheila Rajagopal 1 , Gulzar N. Daya1 , Shay Ben-Aroya2 , Alejandro A. Schäffer1 , Eli Eisenberg4 , Eytan Ruppin 1 ,†, Erez Y. Levanon 2 ,3 , *,†  \n1 Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States  \n2 Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, 5290002, Israel  \n3The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan, 5290002, Israel  \n4 Raymond and Beverly Sackler School of Physics and Astronomy, Tel-Aviv University, Tel Aviv, 6997801, Israel  \n* To whom correspondence should be addressed. Email: [Erez.Levanon@biu.ac.il](Erez.Levanon@biu.ac.il)[ ](Erez.Levanon@biu.ac.il)† Equal contribution.  \nAbstract  \nAdenosine deaminases acting on RNA (ADAR) enzymes constitute a natural cellular mechanism that induces A-to-I(G) editing, introducing genetic changes at the RNA level. Recently, interest in the endogenous-ADAR editor has emerged for correcting genetic mutations, consisting of a programmed oligonucleotide that attracts the native ADAR, thereby offering opportunities for medical therapy. Here, we systematically chart the scope of cancer mutations that endogenous-ADAR can correct. First, analyzing germline single nucleotide variants in cancer predisposition genes, we find that endogenous-ADAR can revert a fifth of them, reducing the risk of cancer development later in life. Second, examining somatic mutations across various cancer types, we find that it has the potential to correct at least one driver mutation in over a third of the samples, suggesting a promising future treatment strategy. We also highlight key driver mutations that are amenable to endogenous-ADAR, and are thus of special clinical interest. As using endogenous-ADAR entails delivering relatively small payloads, the prospects of delivering endogenous-ADARto various cancers seem promising. We expect that the large scope of correctable mutations that are systematically charted here for the first time will pave the way for a new era of cancer treatment options.  \nGraphical abstract  \nIntroduction  \nBase editing is an arsenal of techniques that enable the precise manipulation of the genome sequence by efficiently con-  \nverting nucleotides. Initially explored for inherited diseases, base editing holds the potential to address various genetically driven disorders, as many inherited diseases arise from  \nReceived: December 10, 2024. Revised: March 10, 2025. Editorial Decision: April 8, 2025. Accepted: May 5, 2025 © The Author(s) 2025. Published by Oxford University Press on behalf of NAR Cancer.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https:](https://creativecommons.org/licenses/by/4.0/)[//](https://creativecommons.org/licenses/by/4.0/)[creativecommons.org](https://creativecommons.org/licenses/by/4.0/)[/](https://creativecommons.org/licenses/by/4.0/)[licenses](https://creativecommons.org/licenses/by/4.0/)[/](https://creativecommons.org/licenses/by/4.0/)[by](https://creativecommons.org/licenses/by/4.0/)[/](https://creativecommons.org/licenses/by/4.0/)[4.0](https://creativecommons.org/licenses/by/4.0/)[/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \n2 Merdler-Rabinowicz et al.  \nsingle pathogenic point mutations involving altered nucleotides, referred to as single nucleotide variants (SNVs) [1, 2] . In the context of cancer, the high mutational burden of tumors may appear to constrain the efficacy of such techniques. Yet, we propose that a novel technology utilizing endogenous RNA-editing enzymes [3] may prove bene","cbCaiuQsmtXn7r4b","https://ap.wps.com/l/cbCaiuQsmtXn7r4b","pdf",4300360,"English","# Abstract\n# Introduction\n## Base editing and therapeutic potential\n## Endogenous RNA editing and ADAR mechanism\n## Guide RNA design and cellular readout","[{\"question\":\"What are endogenous-ADAR editors and how do they work?\",\"answer\":\"They use a programmed oligonucleotide to attract native ADAR activity, enabling A-to-I(G) RNA editing at targeted sites for potential therapeutic correction.\"},{\"question\":\"How does the study assess which cancer mutations endogenous-ADAR can correct?\",\"answer\":\"It systematically evaluates correctable mutations by analyzing germline single nucleotide variants in cancer predisposition genes and examining somatic mutations across multiple cancer types.\"},{\"question\":\"What therapeutic value does the study suggest for cancer prevention and treatment?\",\"answer\":\"It suggests that endogenous-ADAR may revert a substantial fraction of predisposition variants and has potential to correct at least one driver mutation in a large portion of samples, supporting future treatment strategies.\"}]","A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment | PDF",1790177051,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04a71bf0992d8fcdc4b1df6a018d228f.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eda94e59c83c955c8e523e5ef0f34d65.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17bc416838565a36d3a90e409b9c379e.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac356ed331b4d308d4af3b00415c50c2.webp",980,1268]